Alnylam Pharmaceuticals

As you may have heard by now, ad revenue alone isn't enough to sustain ongoing efforts to improve our service, which is why we are asking loyal site users like you for help. For every $25 contribution, we're offering 3 months of premium service on a "non-recurring" basis. By reducing the need to click, scroll and wait for pages to load, some of our most popular features save premium members considerable time on every visit. Imagine saving even 2 or 3 minutes each day (to say nothing of 5 or 10 or more). Of course, only you know what your time is worth, so we'll let you do the math & figure out if a test drive makes sense for you. To learn more, click this link to watch a 2-min video tour of our premium service.

CLICK HERE to take advantage of this special offer by making a one-time contribution on our secure payment page

ALNY / Message Board / Read Message

Keyword
Subject

Between			and
Rec'd By

Authored By
Minimum Recs

Msg 34689 of 34715 at 9/12/2019 3:08:53 PM by

In response to msg 34688 by evernewbliss	view thread

I guess the kicker might be if Vutrisiran shows much better efficacy in cardio and Patisiran studies don't show the same benefit.

| More

Recs: 0 Views: 95

view thread Replies
Msg #	Subject	Author	Recs	Date Posted
34690	Re: Sixth Annual RNAi Roundtable Series - TTRsc02 on Monday next week	evernewbliss	1	9/12/2019 3:56:34 PM


	About Us • Contact Us • Follow Us on Twitter • Members Directory • Help Center • Advertise Not a member yet? What are you waiting for? Create Account Want to contribute? Support InvestorVillage by donating © 2003-2019 Investorvillage.com. All rights reserved. User Agreement